Mercer Global Advisors
AXSM icon

Mercer Global Advisors’s Axsome Therapeutics AXSM Stock Holding History

Mercer Global Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693K Buy
2,831
+572
+25% +$124K ﹤0.01% 2019
2026
Q1 		$382K Sell
2,259
-963
-30% -$166K ﹤0.01% 2204
2025
Q4 		$588K Buy
3,222
+1,260
+64% +$176K ﹤0.01% 1758
2025
Q3 		$238K Buy
+1,962
New +$221K ﹤0.01% 2258

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mercer Global Advisors's AXSM Position: Q2 2026 in Review

Mercer Global Advisors increased its Axsome Therapeutics (AXSM) stake by 25% in Q2 2026, buying an estimated $124K and bringing the position to 2,831 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Mercer Global Advisors first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Mercer Global Advisors held 2,831 shares of Axsome Therapeutics worth $693K as of Q2 2026.
  • Mercer Global Advisors bought 572 Axsome Therapeutics shares in Q2 2026, an estimated $124K.
  • Axsome Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2019 holding.
  • Mercer Global Advisors first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.